Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE studyOliver A. Cornely, Sílvia Gómez-Zorrilla, José Miguel Cisneros et al.|Journal of Antimicrobial Chemotherapy|2019Cited by 123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, Surbhi Malhotra‐Kumar, José Miguel Cisneros et al.|The Lancet Infectious Diseases|2024Cited by 98
Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopeniaElena Pérez‐Nadales, Julián Torre‐Cisneros, Maristela Pinheiro Freire et al.|American Journal of Transplantation|2019Cited by 31
Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in SpainRosa M. Jiménez-Rodríguez, José Miguel Cisneros, Guillermo Martín-Gutiérrez et al.|BMJ Open|2022Cited by 2